14 completed. 14 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 14 |
| Phase 2 | 4 | Completed 4 |
Follow BioNTech SE: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age BNT162b2 Vaccine, Placebo - COVID-19, SARS-COV-2 Infection | Phase 3 | Completed | BioNTech SE | 5240 | 2025-12-10 | 2026-10-16 |
| A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 BNT162b2 (2025/2026 formulation) - COVID-19, SARS-COV-2 Infection | Phase 3 | Completed | BioNTech SE | 344 | 2025-10-30 | 2026-08-07 |
| A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) - COVID-19, SARS-COV-2 Infection | Phase 3 | Completed | BioNTech SE | 774 | 2025-07-08 | 2026-06-01 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine - Influenza, COVID-19 | Phase 3 | Completed | BioNTech SE | 8795 | 2023-12-20 | 2025-12-04 |
| A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2) - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 1051 | 2023-08-10 | 2026-04-28 |
| A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose - SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2 | Phase 3 | Completed | BioNTech SE | 4338 | 2022-09-23 | 2026-08-06 |
| A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 Bivalent (WT/OMI BA.4/BA.5) - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 1453 | 2022-07-26 | 2025-10-01 |
| Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age BNT162b2, Placebo, Seasonal Inactivated Influenza Vaccine - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 1134 | 2022-04-20 | 2024-06-12 |
| To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. BNT162b2, Placebo, BNT162b2 OMI - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 16372 | 2021-07-01 | 2025-11-10 |
| A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults BNT162b2 - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 629 | 2021-04-01 | 2022-12-23 |
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 11837 | 2021-03-24 | 2026-05-28 |
| To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 726 | 2021-02-16 | 2024-12-06 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants BNT162b2, BNT162b2.B.1.351 - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | BioNTech SE | 1574 | 2021-02-15 | 2022-12-22 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals BNT162b1, BNT162b2, Placebo - SARS-CoV-2 Infection, COVID-19 | Phase 2 / Phase 3 | Completed | BioNTech SE | 46969 | 2020-04-29 | 2026-03-25 |
COVID-19 (14) · Coronavirus Infections (8) · Coronaviridae Infections (1) · Infections (1) · Influenza, Human (1) · Lung Diseases (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
BNT162 Vaccine (11) · Biological Products (1) · COVID-19 Vaccines (1) · Influenza Vaccines (1)
United States (13) · Brazil (5) · South Africa (4) · Germany (2) · Mexico (2) · Puerto Rico (2) · Spain (2) · Argentina (1) · Australia (1) · Finland (1) · Israel (1) · New Zealand (1) · Poland (1) · Turkey (Türkiye) (1) · United Kingdom (1)
PMID 38400102, PMID 39066372, PMID 39197299, PMID 32785213, PMID 33053279, PMID 33301246, PMID 33524990, PMID 34043894, PMID 34525277, PMID 34752019, PMID 35131133, PMID 35316227, PMID 35320659, PMID 35472295, PMID 35473709, PMID 35739094, PMID 35792746, PMID 36055877, PMID 36652353, PMID 36791162, PMID 36929216, PMID 37527039, PMID 37698774, PMID 38012751, PMID 38016021, PMID 39999538, PMID 40237463, PMID 40396505, PMID 40591130, PMID 41560517, PMID 42042826, PMID 42501282, PMID 42646694
2023 (1)